Xeljanz tofacitinib regulatory update

Pfizer said FDA accepted for review an sNDA for 5 and 10 mg Xeljanz tofacitinib tablets to treat moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy or photot...